Hyperopic Reserve as an Indicator of Myopia Prevention by Atropine (Low-concentration Atropine for Myopia Prevention Study)

Funding

This study was supported in part by the General Research Fund (GRF), Research Grants Council, Hong Kong (14111515 & 14103419 & 14102422 [J.C.Y.] and 14105320 & 14102122 [C.C.T.]); Collaborative Research Fund (C7149-20G [J.C.Y.]); Health and Medical Research Fund (HMRF), Hong Kong (07180826 [X.J.Z.], 09202466 [X.J.Z.], 10210246 [X.J.Z.], 11220196 [X.J.Z.], and 07180256 [L.J.C.]), National Natural Science Foundation of China (82171089 [J.C.Y.]); and the Direct Grants of the Chinese University of Hong Kong, (4054762 & 4054695 [L.J.C.] and 4054121 & 4054199 [J.C.Y.] and 178662514 [J.C.Y.] and 4054770 [X.J.Z.]), the Innovation and Technology Fund (PRP/042/ 19FX, Partnership Research Programme, Jean-Marie Pharmacal Company Limited [J.C.Y.]), the UBS Optimus Foundation Grant 8984 (J.C.Y.); the Centaline Myopia Fund [J.C.Y.]; Start-up Grant, the Chinese University of Hong Kong (X.J.Z.), the CUHK Jockey Club Children’s Eye Care Programme (No grant number); and the CUHK Jockey Club Myopia Prevention Programme (No grant number).